Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder-Reference-Cited by-同舟云学术

Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder

Published:2015-07-01 Issue:7 Volume:72 Page:756
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Ringelstein Marius¹,Ayzenberg Ilya²,Harmel Jens¹,Lauenstein Ann-Sophie³,Lensch Eckart³,Stögbauer Florian⁴,Hellwig Kerstin²,Ellrichmann Gisa²,Stettner Mark¹,Chan Andrew²,Hartung Hans-Peter¹,Kieseier Bernd¹,Gold Ralf²,Aktas Orhan¹,Kleiter Ingo²

Affiliation:

1. Department of Neurology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

2. Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany

3. Deutschen Klinik für Diagnostik Helios Klinik Wiesbaden, Wiesbaden, Germany

4. Department of Neurology, Clinic Osnabrück, Osnabrück, Germany

Publisher

American Medical Association (AMA)

Subject

Clinical Neurology

Cited by 201 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NMOSD and MOGAD: an evolving disease spectrum;Nature Reviews Neurology;2024-09-13

2. Interleukin-6 Signaling Blockade Induces Regulatory Plasmablasts in Neuromyelitis Optica Spectrum Disorder;Neurology Neuroimmunology & Neuroinflammation;2024-07

3. New treatment options for Neuromyelitis optica spectrum disorders (NMOSD);Neurologie pro praxi;2024-06-20

4. Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder;Neurology Neuroimmunology & Neuroinflammation;2024-01

5. Beyond MS;Clinical Aspects of Multiple Sclerosis Essentials and Current Updates;2024